Olaparib

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3960 publications

Mechanistic insights into Nrf2- and PARP1-mediated radioresistance of glioblastoma stem cells under photon, proton, and carbon ion irradiation: An in vitro study.

Mechanistic insights into Nrf2- and PARP1-mediated radioresistance of glioblastoma stem cells under photon, proton, and carbon ion irradiation: An in vitro study.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: August 18, 2026

CD73 inhibition overcomes adaptive immune resistance to PARP inhibiton in models of prostate cancer.

CD73 inhibition overcomes adaptive immune resistance to PARP inhibiton in models of prostate cancer.

Journal: The Journal of clinical investigation
Published: August 18, 2026

DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy.

DNA hypomethylation identifying clinical benefit subgroup of small-cell lung cancer: multi-omics analysis of a phase II trial with durvalumab plus olaparib as maintenance therapy.

Journal: Journal for immunotherapy of cancer
Published: August 05, 2026

Improving effect and mechanism of Bugan Decoction on sperm quality in mice with exercise-induced fatigue via PARP-1

Improving effect and mechanism of Bugan Decoction on sperm quality in mice with exercise-induced fatigue via PARP-1

Journal: Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
Published: August 02, 2026

Defining the Role of Progesterone Signaling in High-Grade Serous Ovarian Cancer Using Fallopian Tube Models.

Defining the Role of Progesterone Signaling in High-Grade Serous Ovarian Cancer Using Fallopian Tube Models.

Journal: Research square
Published: July 29, 2026

Transposable elements shape olaparib response according to BRCA1 status in triple-negative breast cancer.

Transposable elements shape olaparib response according to BRCA1 status in triple-negative breast cancer.

Journal: bioRxiv : the preprint server for biology
Published: July 29, 2026

Efficacy and Safety of Olaparib Combined With Cediranib in the Treatment of Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Efficacy and Safety of Olaparib Combined With Cediranib in the Treatment of Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal: Technology in cancer research & treatment
Published: July 25, 2026

Research on the impact of different chemotherapy and targeted therapy regimens on postoperative disease-free survival in breast cancer patients.

Research on the impact of different chemotherapy and targeted therapy regimens on postoperative disease-free survival in breast cancer patients.

Journal: Pakistan journal of pharmaceutical sciences
Published: July 20, 2026

Comment on "Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial".

Comment on "Olaparib combined with abiraterone in HRR-mutated metastatic hormone-sensitive prostate cancer: a single-arm phase II trial".

Journal: World journal of urology
Published: July 08, 2026

XYL-1 and Olaparib Synergistically Inhibit the Growth of Pancreatic Cancer by Suppressing the SCD1/BRCA1 Signaling Pathway.

XYL-1 and Olaparib Synergistically Inhibit the Growth of Pancreatic Cancer by Suppressing the SCD1/BRCA1 Signaling Pathway.

Journal: Molecules (Basel, Switzerland)
Published: July 07, 2026

Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy.

Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 07, 2026

Reply to: Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy.

Reply to: Olaparib in Metastatic Breast Cancer: The Impact of Prior Cyclin-Dependent Kinase 4 and 6 Inhibitor Exposure on Efficacy.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 07, 2026
Showing 1-12 of 3,960

Last Updated: 09/26/2026